NATCOPHARM · NSE
Natco Pharma Limited
₹814.3
-0.93% (-₹7.65)
Prev. close
₹821.95
Volume
5,59,245
Delivery %
48.3%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Natco Pharma, recommending a buy at ₹914 with a target of ₹980 and a stop loss at ₹880. This recommendation i…” | Sumeet BagadiaChoice Equity Broking | Natco Pharma | MISS | |
| “Recommends buying Natco Pharma at ₹823 with a target of ₹860 and a stop loss at ₹800 for intraday trading.” | Vaishali ParekhPrabhudas Lilladher | Natco Pharma | HIT | |
| “Nuvama raised its target price on Natco Pharma to ₹1,110 from ₹990, maintaining a 'Hold' rating. The brokerage believes …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Natco Pharma | HIT | |
| “Bullish on Natco Pharma; recommends buying at current market price and on dips to ₹980, with a stop loss at ₹950. Target…” | Raja VenkatramanIndependent | Natco Pharma Ltd | MISS | |
| “Bullish on Natco Pharma (NATCOPHARMA), recommending to buy at current market price and on dips to ₹980, with a stop loss…” | Raja VenkatramanNeoTrader | Natco Pharma Ltd | MISS | |
| “Bullish on Natco Pharma for the short-term, recommending a buy at ₹953 with a target of ₹1,010 and a stop loss at ₹925. …” | Nagaraj ShettiHDFC Securities | Natco Pharma Ltd | HIT | |
| “Recommends buying Natco Pharma at ₹905, setting a target of ₹980, and a stop loss at ₹880.” | Vaishali ParekhPrabhudas Lilladher | Natco Pharma Ltd | PENDING | |
| “Recommends buying Natco Pharma at ₹935, targeting ₹1000, with a stop loss at ₹900.” | Vaishali ParekhPrabhudas Lilladher | Natco Pharma Ltd | HIT | |
| “Recommends buying Natco Pharma Ltd (NATCOPHARM) in the range of ₹790-800, setting a target price of ₹840 with a stop los…” | Ganesh DongreAnand Rathi | Natco Pharma Ltd | MISS | |
| “Bullish on Natco Pharma for intraday trading, recommending a buy at ₹1,328 with a target of ₹1,421 and a stop loss at ₹1…” | Sumeet BagadiaChoice Equity Broking | Natco Pharma | MISS | |
| “Recommends buying Natco Pharma at ₹1262.85, targeting ₹1351, with a stop loss at ₹1218. This is based on a technical bre…” | Sumeet BagadiaChoice Equity Broking | Natco Pharma Ltd | MISS | |
| “Recommends buying Natco Pharma in the range of ₹1,285-1,235, targeting ₹1,616 and potentially ₹1,785, expecting a decent…” | Axis Securities AnalysisAxis Securities | Natco Pharma Ltd | MISS |
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Natco Pharma, which has surpassed its 850 resistance zone with high volumes. The stock shows increased moment…” | Rajesh PalviyaAxis Securities | Natco Pharma Ltd | — | |
| “Maintains a 'hold' rating on NATCO Pharma, slashing its target price to ₹1,100 from ₹1,440. This revision follows an "al…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | NATCO Pharma Ltd | — | |
| “Bullish on Natco Pharma Ltd, recommending to buy, hold, and accumulate. The stock decisively surpassed its three-week re…” | Rajesh PalviyaAxis Securities | Natco Pharma Ltd | — |
Fundamentals
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajeev Nannapaneni
Headquarters
Hyderabad
Employees
4,433
Website
natcopharma.co.inExchange
View on NSE ↗Key stats
Market cap
₹15,472.75 Cr
P/E ratio (TTM)
12.4
Dividend yield
0.76%
EPS (TTM)
₹63.37
Beta (1Y · daily vs NIFTY 50)
0.86
Beta (5Y · monthly vs NIFTY 50)
0.92
Shares float
9.21 Cr
EPS · quarter ended Jun 2026
₹11.53
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,052.10 Cr | ₹1,944.80 Cr | ₹2,707.10 Cr | ₹3,998.80 Cr | ₹4,429.50 Cr | ₹4,078.30 Cr | |
EBITDA | ₹709.80 Cr | ₹362.50 Cr | ₹1,040.20 Cr | ₹1,879.50 Cr | ₹2,550.50 Cr | ₹1,734.10 Cr |
| ₹440.90 Cr | ₹170.00 Cr | ₹715.30 Cr | ₹1,388.30 Cr | ₹1,885.40 Cr | ₹1,418.50 Cr | |
Diluted EPS | ₹24.16 | ₹9.32 | ₹39.18 | ₹77.34 | ₹105.26 | ₹79.2 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Pretax income, Tax provision, Interest expense, Other income have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,791.90 Cr | ₹5,109.10 Cr | ₹5,657.40 Cr | ₹6,906.30 Cr | ₹8,630.80 Cr | ₹11,073.70 Cr | |
| — | — | ₹176.10 Cr | ₹371.20 Cr | ₹279.40 Cr | ₹713.90 Cr | |
Stockholders' equity | ₹4,121.60 Cr | ₹4,263.60 Cr | ₹4,873.80 Cr | ₹5,853.10 Cr | ₹7,607.00 Cr | ₹9,221.10 Cr |
Fixed assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹298.80 Cr | ₹46.50 Cr | ₹849.10 Cr | ₹1,211.60 Cr | ₹1,696.80 Cr | ₹1,768.30 Cr | |
Investing cash flow | ₹-103.30 Cr | ₹-5.30 Cr | ₹-477.10 Cr | ₹-1,032.70 Cr | ₹-1,414.50 Cr | ₹-2,081.70 Cr |
| ₹-185.70 Cr | ₹34.80 Cr | ₹-363.00 Cr | ₹-246.90 Cr | ₹-210.70 Cr | ₹297.50 Cr | |
Capital expenditure | ₹-441.50 Cr | ₹-272.00 Cr | ₹-205.60 Cr | ₹-358.70 Cr | ₹-511.60 Cr | ₹-391.10 Cr |
End cash position | ₹25.80 Cr | ₹111.10 Cr | ₹131.90 Cr | ₹70.40 Cr | ₹120.00 Cr | ₹198.90 Cr |
Depreciation & amortization, Change in working capital, Debt issued, Dividends paid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23 | Jun 23 | Sep 23–Jun 24(4Q) | Sep 24–Dec 24(2Q) | Mar 25–Jun 25(2Q) | Sep 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 48.87% | 48.86% | 48.81% | 48.80% | 48.82% | 48.84% | 49.76% | 49.71% | 49.62% | 49.56% | 49.48% | 49.42% |
| Public | 51.13% | 51.14% | 51.19% | 51.20% | 51.18% | 51.16% | 50.24% | 50.29% | 50.38% | 50.44% | 50.52% | 50.58% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Natco Pharma Limited | ₹15,332.49 Cr | ₹788.75 | 12.3 | 1.66 | 15.4% | 0.08 | -8.3% | -3.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.